dc.creatorStarcevic, Vladan
dc.creatorBerle, David
dc.creatordo Rosario, Maria Conceicao [UNIFESP]
dc.creatorBrakoulias, Vlasios
dc.creatorFerrao, Ygor A.
dc.creatorViswasam, Kirupamani
dc.creatorShavitt, Roseli
dc.creatorMiguel, Euripedes
dc.creatorFontenelle, Leonardo F.
dc.date.accessioned2019-01-21T10:30:19Z
dc.date.accessioned2022-10-07T20:59:21Z
dc.date.available2019-01-21T10:30:19Z
dc.date.available2022-10-07T20:59:21Z
dc.date.created2019-01-21T10:30:19Z
dc.date.issued2016
dc.identifierInternational Clinical Psychopharmacology. Philadelphia, v. 31, n. 1, p. 27-33, 2016.
dc.identifier0268-1315
dc.identifierhttp://repositorio.unifesp.br/handle/11600/49704
dc.identifier10.1097/YIC.0000000000000100
dc.identifierWOS:000366691200004
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/4025725
dc.description.abstractThis study aimed to determine the frequency of benzodiazepine (BDZ) use in a large sample of patients with obsessive-compulsive disorder (OCD) and ascertain the type of BDZ used and the correlates and predictors of BDZ use in OCD. The sample consisted of 955 patients with OCD from a comprehensive, cross-sectional, multicentre study conducted by the Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders between 2003 and 2009. The rate of BDZ use over time in this OCD sample was 38.4%. Of individuals taking BDZs, 96.7% used them in combination with other medications, usually serotonin reuptake inhibitors. The most commonly used BDZ was clonazepam. Current age, current level of anxiety and number of additional medications for OCD taken over time significantly predicted BDZ use. This is the first study to comprehensively examine BDZ use in OCD patients, demonstrating that it is relatively common, despite recommendations from treatment guidelines. Use of BDZs in combination with several other medications over time and in patients with marked anxiety suggests that OCD patients taking BDZs may be more complex and more difficult to manage. This calls for further research and clarification of the role of BDZs in the treatment of OCD.
dc.languageeng
dc.publisherLippincott Williams & Wilkins
dc.relationInternational Clinical Psychopharmacology
dc.rightsAcesso restrito
dc.subjectanxiety
dc.subjectbenzodiazepines
dc.subjectclonazepam
dc.subjectobsessive-compulsive disorder
dc.subjecttreatment guidelinesPharmacological-Treatment
dc.subjectPosttraumatic-Stress
dc.subjectClonazepam Treatment
dc.subjectPanic Disorder
dc.subjectAnxiety
dc.subjectPopulation
dc.subjectBrazil
dc.subjectClomipramine
dc.subjectGuidelines
dc.subjectPatterns
dc.titleUse of benzodiazepines in obsessive-compulsive disorder
dc.typeArtigo


Este ítem pertenece a la siguiente institución